Immunological recovery, failure and factors associated with CD-4 T-cells progression over time, among adolescents and adults living with HIV on Antiretroviral Therapy in Northern Ethiopia: A retrospective cross sectional study


Autoři: Abraham Aregay Desta aff001;  Tewolde Wubayehu Woldearegay aff001;  Asfawosen Aregay Berhe aff001;  Nesredin Futwi aff001;  Goyitom Gebremedhn Gebru aff001;  Hagos Godefay aff002
Působiště autorů: Tigray Health Research Institute, Mekelle, Tigray, Ethiopia aff001;  Tigray Regional Health Bureau, Mekelle, Tigray, Ethiopia aff002
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
doi: 10.1371/journal.pone.0226293

Souhrn

Background

This study was aimed to assess immunological recovery, failure, and factors associated with CD-4 T-cells progression over time, among adolescents and adults living with HIV on Antiretroviral Therapy in Northern Ethiopia.

Methods

A retrospective cross sectional study was done on 19,525 HIV patients on ART. Data were collected using a data retrieval checklist from a database. All eligible data in the database were exported to Microsoft excel 2010 and then data verification and filtration were done before exporting to STATA 14.0 for analysis. Factors associated with recent CD-4 count were modeled by using Generalized Linear Model poison family.

Results

Among the patients with advanced HIV infection (< 200 CD-4 T-cell/ mm3) at baseline, only 28.35%, 95% CI (27.45–29.26) of them had immunological recovery (≥ 500 T-cells/mm3). Only 2.14%, 95%CI (1.94%- 2.35%) of the patients had immunological failure. Baseline CD-4 count (Incidence Rate Ratio (IRR) = 1.0007, 95%CI = 1.00069–1.00078), patients from military health care facility (IRR = 1.11, 95%CI = 1.06–1.16), good adherence (IRR = 1.12, 95%CI = 1.04–1.21) and viral load suppression (IRR = 1.31, 95%CI = 1.28–1.33) were positively associated with recent CD-4 count in the full model. Whereas, being male (IRR = 0.85, 95%CI = 0.83–0.86), patients with on Anti-Retroviral Therapy (ART) regimen of 1e (TDF-3TC-EFV), 2f (AZT-3TC-ATV/r), and 2h (TDF-3TC-ATV/r) (IRR = 0.92, 95%CI = 0.91–0.94), (IRR = 0.65, 95%CI = 0.55–0.76) and (IRR = 0.71, 95%CI = 0.63–0.81) respectively were negatively associated with the recent CD-4 count in the full model.

Conclusions

Immunological recovery was achieved by 1/3 of the patients despite being on highly active ART (HAART). Therefore, intensive adherence counseling, follow-up and support should be focused on patients with viral non suppression to enhance immunological recovery.

Klíčová slova:

Ethiopia – Health care facilities – HIV infections – T cells – Viral load – Military medicine


Zdroje

1. UNAIDS. Factsheet–World AIDS day 201 8: 2017 Global HIV Statistics. Geneva: UNAIDS. Available from: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf [Accessed 14th Feburary 2019]

2. EPHI, PEPFAR, CDC, Westat, ICAP. ETHIOPIA POPULATION-BASED HIV IMPACT ASSESSMENT EPHIA 2017–2018. SUMMARY SHEET: PRELIMINARY FINDINGS. Available from: https://phia.icap.columbia.edu/wp-content/uploads/2018/12/3511%E2%80%A2EPHIA-Summary-Sheet_v30.pdf [Accessed 16th January 2019]

3. Tigray Regional Health Bureau. HMIS report 2018. Mekelle, Ethiopia: Tigray Regional Health Bureau; 2018

4. Wang H, Wolock TM, Carter A, Nguyen G, Kyu HH, Gakidou E, et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV. 2016;3(8):e361–87. doi: 10.1016/S2352-3018(16)30087-X 27470028

5. Mulu A, Liebert UG, Maier M. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. BMC Infectious Diseases. 2014; 14:28 doi: 10.1186/1471-2334-14-28 24422906

6. European AIDS Clinical Society. Guidelines Version 8.2, January, 2017. Available from: http://www.eacsociety.org/files/guidelines_8.2- english.pdf [Accessed 20th Feburary 2019].

7. Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS. 1999; 13:951–56. doi: 10.1097/00002030-199905280-00011 10371176

8. Clavel F, Hance AJ. Medical progress: HIV drug resistance. N Engl J Med. 2004; 350: 1023–35. doi: 10.1056/NEJMra025195 14999114

9. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: multicentre study. Br Med J. 1997; 315: 1194–99

10. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization; 2010.

11. WHO. Consolidated guidelines on the use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a public health approach. Geneva: WHO; 2013

12. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach- 2nd ed. Geneva, Switzerland: WHO; 2016.

13. Hamers RL, Kityo C, Lange JM, de Wit TF, Mugyenyi P. Global threat from drug resistant HIV in sub-Saharan Africa. BMJ. 2012; 344: e4159 doi: 10.1136/bmj.e4159 22709963

14. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington: Department of Health and Human Services; 2012. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf [Accessed 11th Feburary 2019]

15. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008; 13(2): 25–36.

16. Ayele G, Tessema B, Amsalu A, Ferede G, Yismaw G. Prevalence and associated factors of treatment failure among HIV/AIDS patients on HAART attending University of Gondar Referral Hospital Northwest Ethiopia. BMC Immunology. 2018; 19:37 doi: 10.1186/s12865-018-0278-4 30558580

17. Hailu GG, Hagos DG, Hagos AK, Wasihun AG, Dejene TA. Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia. PLoS ONE. 2018; 13 (5): e0196259. doi: 10.1371/journal.pone.0196259 29715323

18. Wikipedia, the free encyclopedia. Available from: https://en.wikipedia.org/wiki/Tigray_Region [Accessed on Sep, 2019]

19. Tigray Regional Health Bureau. Regional health Profile 2008 Ethiopian Fiscal Year (EFY). Mekelle, Ethiopia: Tigray Regional Health Bureau, 2016

20. Taylor J. Poisson Regression: Introduction to Applied Statistics. Stanford University. 2009.

21. Federal Democratic Republic of Ethiopia Ministry of health. NATIONAL GUIDELINES FOR COMPREHENSIVE HIV PREVENTION, CARE AND TREATMENT. Version 5, 2017. Addis Ababa: Federal Ministry of Health Ethiopia.

22. Abdissa A, Yilma D, Fonager J, AudelinM A, Christensen HL, Mette FO et al. Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. BMC Infectious Diseases. 2014; 14:181. doi: 10.1186/1471-2334-14-181 24708645

23. Teshome W, Tefera A. Detection of immunological treatment failure among HIV infected patients in Ethiopia: a retrospective cohort study. BMC Immunology. 2015; 16: 55. doi: 10.1186/s12865-015-0120-1 26376828

24. Teshome YY, Yalew AW. Magnitude and Predictors of Anti-Retroviral Treatment (ART) Failure in Private Health Facilities in Addis Ababa, Ethiopia. PLoS ONE. 2015; 10(5): e0126026. doi: 10.1371/journal.pone.0126026 25946065

25. Brhane BG, Nibret E, Abay GK. HIV/AIDS Treatment Failure and its Determinant Factors among First Line HAART Patients at Felege-Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia. J AIDS Clin Res. 2017; 8: 744. doi: 10.4172/2155–6113.1000744

26. Yirdaw KD, Hattingh S. Prevalence and Predictors of Immunological Failure among HIV Patients on HAART in Southern Ethiopia. PLoS ONE. 2015; 10(5): e0125826. doi: 10.1371/journal.pone.0125826 25961732

27. Sang RKA, Miruka FO. Factors Associated with Virologic Failure Amongst Adults on Antiretroviral Therapy in Nyanza Region, Kenya. IOSR-JDMS. 2016; 15(7):108–121.

28. Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E et al. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study. J AntimicrobChemother. 2015; 70(6):1881–4. https://doi.org/10.1093/jac/dkv030

29. Wakayo BU, Getnet F, Teka, Feyera T. Analysis on effects of diets on antiretroviral therapy (ART) immune response among HIV/AIDS Patients in Eastern Ethiopia: Particular emphasis to camel dairy consumption. African journal of pharmacy and pharmacology. 2016; doi: 10.5897/AJPP2015.4488

30. Gezie LD, Gelaye KA, Worku AG, Ayele TA. Teshome DF. Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia. BMC Res Notes. 2017; 10:277 doi: 10.1186/s13104-017-2602-0 28705176

31. Gezie LD. Predictors of CD4 count over time among HIV patients initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia: multilevel analysis. BMC Res Notes. 2016; 9:377 doi: 10.1186/s13104-016-2182-4 27475982

32. Kim KH, Yi J, Lee HS. The CD4 slope can be a predictor of immunologic recovery in advanced HIV Patients: a case control study. J Intern Med. 2015;30(5):705.

33. Kelley FC, Kitchen MRC, Hunt WP, Rodriguez B, Hecht MF, Kitahata M, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009; 48(6):787–94. doi: 10.1086/597093 19193107

34. Addisu G, Biniam M, Beyene M, Meseret W, Lealem G. Establishment of normal reference intervals for CD3+, CD4+, CD8+, and CD4+ to CD8+ ratio of T lymphocytes in HIV negative adults from University of Gondar Hospital, North West Ethiopia. Cairo: Hindawi Publishing Corporation; 2014.

35. De La Hoz JM, Bolaño L, CaÂrdenas O, GonzaÂlez R, Sabbag J, Palacio Let al. Charactrization of treatment failure in HIV positive patients in the Colombian Caribbean region. Colomb med(Cali). 2014; 45(4):162–167.

36. Raffi F, Le Moing V, Assuied A, Habak S, Spire B, Cazanave C et al. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course. J Antimicrob Chemother. 2017; 72(1):240–245. doi: 10.1093/jac/dkw369 27629069

37. Gandhi TR, Spritzler J, Chan E, Asmuth MD, Rodriguez B, Merigan CT, et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr. 2006;42(4):426–34. doi: 10.1097/01.qai.0000226789.51992.3f 16810109

38. Smith JC, Sabin AC, Youle SM, Loes KS, Lampe CF, Madge S, et al. Factors influencing increases in CD4 cell counts of HIV positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis. 2004;190:1860–8. doi: 10.1086/425075 15499544

39. Florence E, Lundgren J, Dreezen C, Fischer M, Kirk O, Blaxhult A, et al. Factors associated with a reduced CD4+ lymphocyte count response to HAART despite full viral suppression in the Euro SIDA study. HIV Med. 2003;4(3):255–62. doi: 10.1046/j.1468-1293.2003.00156.x 12859325

40. Viard JP, Mocroft A, Chiesi A, Kirk O, Røge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001; 183 (1290–4) doi: 10.1086/319678 11262215

41. Kaufmann GR, Bloch M, Finlayson R, Zaunders JJ, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS. 2002; 16 (359–67) doi: 10.1097/00002030-200202150-00007 11834947

42. Montarroyos RU, Miranda-Filho CD, Ce´sar CC, Souza VW, Lacerda RH, Albuquerque MP, et al. Factors related to changes in CD4+ T-Cell counts over time in patients living with HIV/AIDS: a multilevel analysis. PLoS ONE. 2014;9(2):e84276. doi: 10.1371/journal.pone.0084276 24505247

43. Addisu A, Dagim A, Tadele E, Adissu A, Mussie A, Filmon K. CD4 cell count trends after commencement of antiretroviral therapy among HIV infected patients in Tigray, northern Ethiopia: a retrospective cross-sectional study. PLoS ONE. 2015;10(3):e0122583. doi: 10.1371/journal.pone.0122583 25816222

44. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: literature review. J Adv Nurs. 2005;49(6):616–23. doi: 10.1111/j.1365-2648.2004.03331.x 15737222

45. Kwobach CM, Braitstein P, Koech JK, Simiyu G, Mwanqi AW, Siika AM et al. Factors associated with late engagement to HIV care in Western Kenya: a cross-sectional study. J Int Assoc Provid AIDS Care. 2015. pii 2325957414567682. doi: 10.1177/2325957414567682 25589304

46. Mojumdar K, Vajpayee M, Chauhan N, Mendiratta S. Late presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population. BMC Public Health. 2010;10:416. doi: 10.1186/1471-2458-10-416 20626905

47. Gea-Banacloche J, LH LC. Immune reconstitution in HIV infection. AIDS. 1999;13(Suppl A):S25–38.

48. Edathodu J, Ali B, Alrajhi AA. CD4 validation for the World Health Organization classification and clinical staging of HIV/AIDS in a developing country. International Journal of Infectious Diseases. 2009; 13 (2):243–246. doi: 10.1016/j.ijid.2007.12.017 18945632

49. Ilovi CS, Lule GN, Obel AO, Irimu HM. Correlation of WHO clinical staging with CD4 counts in adult HIV/AIDS patients at Kenyatta National Hospital, Nairobi. East Afr Med J. 2011 Feb;88(2):65–70. 24968593

50. Ilovi CS, Lule GN, Obel AO, Irimu HM. CORRELATION OF WHO CLINICAL STAGING WITH CD4 COUNTS IN ADULT HIV/AIDS PATIENTS AT KENYATTA NATIONAL HOSPITAL, NAIROBI. East African Medical Journal. 2011; 88(2)

51. Ojha CR, Shakya G, Dumre SP. Virological and Immunological Status of the People Living with HIV/AIDS Undergoing ART Treatment in Nepal. BioMed Research International. 2016; Article ID 6817325, 7 pages http://dx.doi.org/10.1155/2016/6817325 available at: https://www.hindawi.com/journals/bmri/2016/6817325/ [Accessed on 12th March 2019]

52. Puthanakit T, Kerr SJ, Ananworanich J, Bunupuradah T, Boonrak P and Sirisanthana V. Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral Therapy. PediatrInfect Dis J. 2009; 28(6): 488–492.

53. Raja K, Chandrasekar C, Krishnarajasekhar OR, Ravichandran N, Kumar S, Manoharan G, Sharmila IA. Predicting Virological Failure with Immunological Criteria in First Line ART Patients in a Resource Poor Setting. World Journal of AIDS. 2014; 4: 413–421.

54. Smith SR, Rublein JC, Marcus C, Brock TP, Chesney MA. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns. 2003; 50:187–99 doi: 10.1016/s0738-3991(02)00127-1 12781934

55. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G et al. Factors Associated with Virological Non suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015. BMC Infectious Diseases. 2017; 17:326 doi: 10.1186/s12879-017-2428-3 28468608


Článek vyšel v časopise

PLOS One


2019 Číslo 12